YOKNEAM, Israel, Aug. 6, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences and events in August:
9th Annual Needham Virtual MedTech & Diagnostics Conference
Presenters: Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial Officer
Format: Virtual one-on-one meetings
When: Monday, Aug. 12
Canaccord 44th Annual Global Growth Conference
Presenters: Yair Malca, Chief Financial Officer
Format: In-person fireside chat moderated by Caitlin Cronin, Director of MedTech Equity Research, and meetings
When: Wednesday, Aug. 14 at 2:00 pm ET
A live webcast of the presentation can be accessed here.
About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
Investor Relations Contact:
Miri Segal-Scharia
MS-IR LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
917-607-8654
Last Trade: | US$15.18 |
Daily Change: | -0.05 -0.33 |
Daily Volume: | 1,755,562 |
Market Cap: | US$924.770M |
April 28, 2025 March 03, 2025 February 04, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load